See more : Clarus Corporation (CLAR) Income Statement Analysis – Financial Results
Complete financial analysis of Apogee Therapeutics, Inc. (APGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Apogee Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lewinsky-Ofer Ltd. (LEOF.TA) Income Statement Analysis – Financial Results
- Vaudoise Assurances Holding SA (0QN7.L) Income Statement Analysis – Financial Results
- Brighton-Best International (Taiwan) Inc. (8415.TWO) Income Statement Analysis – Financial Results
- Sojitz Corporation (SZHFF) Income Statement Analysis – Financial Results
- Aroundtown SA (0RUH.L) Income Statement Analysis – Financial Results
Apogee Therapeutics, Inc. (APGE)
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 68.42M | 27.79M |
| General & Administrative | 24.58M | 2.94M |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 24.58M | 2.94M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 93.00M | 30.73M |
| Cost & Expenses | 93.00M | 30.73M |
| Interest Income | 9.02M | 92.00K |
| Interest Expense | 0.00 | 9.15M |
| Depreciation & Amortization | 9.02M | 33.52M |
| EBITDA | -83.99M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -93.00M | -30.73M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.02M | -9.06M |
| Income Before Tax | -83.99M | -39.79M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -33.52K |
| Net Income | -83.99M | -39.79M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -3.36 | -0.79 |
| EPS Diluted | -3.36 | -0.79 |
| Weighted Avg Shares Out | 25.01M | 50.67M |
| Weighted Avg Shares Out (Dil) | 25.01M | 50.67M |
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day
Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep and sustained inhibition of biomarkers
Apogee Therapeutics Announces Agenda for Virtual R&D Day
SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for...
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments Company to highlight progress across its pipeline and showcase its path to reshaping the standard...
Apogee Therapeutics Earnings Preview: APG777's Potential In Atopic Dermatitis
Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing and potential applications in asthma, COPD, and psoriasis. APGE's investigational pipeline includes APG808 and APG990, targeting different inflammatory pathways, enhancing its potential in the I&I market. APGE's...
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for...
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting
SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for...
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit
SAN FRANCISCO and WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for...
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer
SAN FRANCISCO and WALTHAM, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2025 Initiation of the first clinical trial of APG777 and APG990 combination expected to commence in 2025 with the potential for greater efficacy in atopic dermatitis and...
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy...
Source: https://incomestatements.info
Category: Stock Reports